MYO18B promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR signaling pathway

被引:0
作者
Zhenyu Zhang
Jinfeng Zhu
Yansong Huang
Weibing Li
Hongqiu Cheng
机构
[1] Shenzhen Pingshan District People’s Hospital,Department of Traditional Chinese Medicine
[2] Nantong Hospital of Traditional Chinese Medicine,Department of Traditional Chinese Medicine
[3] The Second Affiliated Hospital of Shantou University Medical College,Department of Infectious Diseases
来源
Diagnostic Pathology | / 13卷
关键词
Hepatocellular carcinoma; PI3K/AKT/mTOR signaling pathway; Prognosis;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 136 条
  • [1] Marrero Jorge A.(2018)Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases Hepatology 68 723-750
  • [2] Kulik Laura M.(2014)Hepatocellular carcinoma epidemiology Best Pract Res Clin Gastroenterol 28 753-770
  • [3] Sirlin Claude B.(2016)Cancer and liver cirrhosis: implications on prognosis and management ESMO Open 1 e000042-799
  • [4] Zhu Andrew X.(2012)Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis Cancer Epidemiol Biomark Prev 21 793-1314
  • [5] Finn Richard S.(2018)Hepatocellular carcinoma Lancet 391 1301-43
  • [6] Abecassis Michael M.(2015)Evaluation and management of hepatocellular carcinoma Clin Liver Dis 19 23-137
  • [7] Roberts Lewis R.(2011)Genetic and epigenetic signatures in human hepatocellular carcinoma: a systematic review Curr Genomics 12 130-9095
  • [8] Heimbach Julie K.(2016)Genetic alterations in hepatocellular carcinoma: an update World J Gastroenterol 22 9069-1181
  • [9] Bosetti C(2006)Serum tumor markers for detection of hepatocellular carcinoma World J Gastroenterol 12 1175-245
  • [10] Turati F(2015)Decrease expression and clinicopathological significance of miR-148a with poor survival in hepatocellular carcinoma tissues Diagn Pathol 10 135-1763